Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
Sponsor: Zhejiang Wenda Pharma Technology LTD.
Summary
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2024-12-31
Completion Date
2025-11-30
Last Updated
2025-04-11
Healthy Volunteers
No
Conditions
Interventions
WD-890 tablet
Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
WD-890 tablet
Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
WD-890 tablet
Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.
Placebo
Participants will receive placebo QD from Week 0 through Week 16.
Locations (1)
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College
Nanjing, Jiangsu, China